Form 8-K for ARIAD PHARMACEUTICALS INC
Results of Operations and Financial Condition, Regulation FD Disclosure
ITEM 2.02 Results of Operations and Financial Condition.In a press release dated February 23, 2016, ARIAD Pharmaceuticals, Inc. (the “Company”) announced financial results for the fourth quarter and full year ended December 31, 2015 and issued 2016 product revenue guidance. Additionally, the Company provided an update on corporate developments and key objectives for 2016. A copy of the press release is attached hereto as Exhibit 99.1. The information under the headings “2015 Fourth Quarter and Full-Year Financial Results,” “Today’s Conference Call at 8:30 a.m. ET” and the condensed consolidated financial information included in the press release are incorporated by reference into this Item 2.02 of this Current Report on Form 8-K.
ITEM 7.01 Regulation FD Disclosure.In the press release dated February 23, 2016, the Company also provided product revenue guidance for 2016, as well as upcoming investor meetings. The information set forth under the headings “2016 Product Revenue Guidance” and “Upcoming Investor Meetings” in the press release are incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.
ITEM 8.01 Other Events.In the press release dated February 23, 2016, the Company also provided an update on its Iclusig�, brigatinib and pipeline programs. The second paragraph of the press release and the information set forth under the heading “Research and Development Progress and Key Objectives,” together with the forward-looking statement disclaimer at the end of the press release, are incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.
ITEM 9.01 Financial Statements and Exhibits.
99.1 Press release dated February 23, 2016.
The press release may contain hypertext links to information on our websites. The information on our websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.
The portions of the press release incorporated by reference into Item 8.01 of this Current Report on Form 8-K are being filed pursuant to such item. The remaining portions of the press release are being furnished pursuant to Items 2.02 and 7.01 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.